Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000950170-25-098552·BridgeBio Oncology Therapeutics, Inc.
Schedule 13G ownership disclosure
HELIX ACQUISITION CORP II
Class A Ordinary Shares, par value $0.0001 per share · CUSIP: G4444H101
Event date: 2025-07-17
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Sculptor Capital LP
Shares: 967,460 · Class: 5.12%
- Sculptor Capital II LP
Shares: 967,460 · Class: 5.12%
- Sculptor Capital Holding Corp
Shares: 967,460 · Class: 5.12%
- Sculptor Capital Holding II LLC
Shares: 967,460 · Class: 5.12%
- Sculptor Capital Management, Inc.
Shares: 967,460 · Class: 5.12%
- Sculptor Master Fund, Ltd.
Shares: 967,460 · Class: 5.12%
- Sculptor Special Funding, LP
Shares: 967,460 · Class: 5.12%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-098552
- Form type
- SCHEDULE 13G
- Filer
- BridgeBio Oncology Therapeutics, Inc.
- CIK
- CIK 1869105
- Filed
- Jul 24, 2025
- Reporting period
- Jul 17, 2025
- Description
- Schedule 13G beneficial ownership